Tenovin-6 Hydrochloride

Assays are carried out using purified components in the Fluor de Lys Fluorescent Assay Systems. Relevant FdL substrates are used at 7 μM and NAD⁺ at 1 mM. Tenovins are solubilized in DMSO with the final DSMO concentration in the reaction being less than 0.25%. For SirT1 and HDAC8, one unit of enzyme is used per reaction, and for SirT2 and SirT3, five units is used per reaction. Reactions are carried out at 37°C for 1 hr.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

The MTS assay is used to evaluate cell viability. UM cells are seeded into each well of 96-well plates (5,000 cells/well) and treated the next day with control or Tenovin-6 in an increasing concentrations from 0 to 20 μM for 68 h, and then MTS is added at 20 μL/well to be read at a wave length of 490 nm, the IC₅₀ is determined by curve fitting of the sigmoidal dose-response curve.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Female SCID mice are injected subcutaneously with 1×10⁶ ARN8 cells suspended in matrigel. Tumors are allowed to reach a size of approximately 10 mm³. Tenovin-6 is administered daily at 50 mg/kg by intraperitoneal injection. Control animals are treated with vehicle solution containing cyclodextrin 20% (w/v) and DMSO 10% (v/v). Tumor diameters are measured using calipers, and volumes are calculated using the equation V=π4/3[(d1 + d2)/4]³. Median values of tumor size are calculated for each time point as well as the corresponding 95% confidence intervals. Comparison of control and drug-treated tumor size distributions are made by Mann-Whitney U-test. An alpha-level of 0.05 is considered appropriate for determination of statistical significance.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.